⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Official Title: A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma

Study ID: NCT06011109

Interventions

APG-157

Study Description

Brief Summary: The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab as standard of care.

Detailed Description: The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma who have previously progressed on bevacizumab alone. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging Additional aims include: * characterization of pharmacokinetics (PK) of APG-157 in the presence of bevacizumab; and * optionally serum changes in VEGF and HIF-1 alpha, if the study shows preliminary indication of efficacy The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of 6 pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab and be present for scheduled visits and examinations as standard of care.

Eligibility

Minimum Age: 19 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Mayo Clinic, Rochester, Minnesota, United States

University of Nebraska Medical Center, Omaha, Nebraska, United States

Contact Details

Name: Nicole Shonka, MD

Affiliation: University of Nebraska

Role: PRINCIPAL_INVESTIGATOR

Name: Joon Uhm, MD

Affiliation: Mayo Clinic

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: